Trials / Completed
CompletedNCT03642717
Regulatory Request NIS in Korea
A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE DUO® (Empagliflozin/Metformin, 5/500mg, 5/850mg, 5/1000mg, 12.5/500mg, 12.5/850mg, 12.5/1000mg) in Korean Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 658 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To monitor the safety profile and effectiveness of JARDIANCE DUO® in Korean patients with type 2 diabetes mellitus in a routine clinical practice setting
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JARDIANCE DUO® | empagliflozin and metformin |
Timeline
- Start date
- 2018-08-21
- Primary completion
- 2020-04-30
- Completion
- 2020-04-30
- First posted
- 2018-08-22
- Last updated
- 2021-05-21
- Results posted
- 2021-05-21
Locations
20 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03642717. Inclusion in this directory is not an endorsement.